Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. - Wikidata - awgldk - TriplyDB

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

http://www.wikidata.org/entity/Q35754209

about

Recent advances in the diagnosis and treatment of childhood tuberculosis Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.Latent tuberculosis infection: myths, models, and molecular mechanisms New approaches in the diagnosis and treatment of latent tuberculosis infection The use of anti-tuberculosis therapy for latent TB infection Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Update in tuberculosis 2005.Rifapentine for the treatment of pulmonary tuberculosis.DNA vaccines against mycobacterial diseases.Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.Chemotherapeutic interventions against tuberculosis New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.A replication clock for Mycobacterium tuberculosis.Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.Fighting tuberculosis: old drugs, new formulations.Targeting persisters for tuberculosis control Current management options for latent tuberculosis: a review.New therapeutic approach for latent tuberculosis infection Latent tuberculosis in kidney and liver transplant patients: a review of treatment practices and outcomes.Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.Rifapentine for the treatment of latent tuberculosis.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis.Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck DNA vaccines against mycobacterial diseases Protective efficacy of different strategies employingMycobacterium lepraeheat-shock protein 65 against tuberculosis

P2860

Q26797426-40414AD5-E6F4-4FE7-BD1C-D684E230B0D5 Q28478920-43A06447-3AB7-47DC-968F-05B574B41AB9 Q28479103-FC2F1704-683C-4DB3-B082-9A4110C62C47 Q33623003-7D111690-C91D-40BF-8179-6C48D88FA377 Q33768799-50209281-61C9-4D99-AEBB-8D2772A9535E Q34297816-9C542AC6-DEA1-412F-A692-4A7C0C7C892F Q34419185-D64BD8DB-CB04-4B09-A565-82BDF643AEF9 Q35026573-5FF86CB4-2A6F-44F8-A31C-C7936E815142 Q35527885-4CE09EC9-56A1-48DC-AFBA-1718F4C76562 Q36403165-B6C9CFFD-3729-4AFC-8FC9-C343881263A9 Q36643657-C22DB3BF-4E17-4895-930F-599D5D16858B Q36895737-F81BCBC9-D7BD-42DC-AC12-B20892BA6DEC Q37144919-555299E7-7B4C-473A-A941-B3B1C79F7A28 Q37148764-12D37EA3-013B-49B4-9714-983E8A05BE51 Q37346929-D125214B-628E-4557-95D6-522BB3A2E326 Q37426997-17D7BCFC-35BB-462E-B3BB-398C447B8180 Q37443290-6EF31B4C-6104-42E4-A6DC-E1F334DCEBBF Q37505396-F9D5E99F-0EED-402A-863D-5D9E709D56F1 Q37579212-212BD11B-4BA0-496C-B659-6F3D57101196 Q37990720-8494BE87-028C-4DB5-9A87-D5D572320F12 Q38066198-2836A0B0-E6AB-4944-82DD-499B692C41A6 Q38265483-1E57FE04-71EF-4BF0-9285-82D8ED991F98 Q38564576-EE42D4CB-C6DD-4F11-9248-0978BF4DDB35 Q38886442-A44BA50F-7D0B-48FA-AB09-4BCE1C58D4C4 Q38933165-1534ABC4-796E-4014-A519-C76809B86FCC Q40095703-BB19C36C-447F-49FA-9B2D-1984B7662991 Q41480039-3A3DACE0-AA03-48E3-A715-743FF5AE32F9 Q56786021-C3335238-88F3-4FFD-8BB7-7F54FACA5861 Q57203115-9EA248C9-161E-47EF-B9A3-35B9EDD52234 Q58863716-C6A8D122-8C8D-40F7-AFA9-840E2C15FCDA

P2860

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

http://www.wikidata.org/entity/Q35754209

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Rifapentine, moxifloxacin, or ...... tuberculosis in a mouse model.

@ast

Rifapentine, moxifloxacin, or ...... tuberculosis in a mouse model.

@en

type

label

Rifapentine, moxifloxacin, or ...... tuberculosis in a mouse model.

@ast

Rifapentine, moxifloxacin, or ...... tuberculosis in a mouse model.

@en

prefLabel

Rifapentine, moxifloxacin, or ...... tuberculosis in a mouse model.

@ast

Rifapentine, moxifloxacin, or ...... tuberculosis in a mouse model.

@en

P1433

Q35754209-798BDD05-C825-4AA7-AEFB-F47721861F4B

P1476

Q35754209-4B7916AC-183A-43D4-A570-ACCDF5AB3DB9

P2093

Q35754209-1935F984-7BF0-4A62-9AF2-2EB05F2429A4

Q35754209-324B8423-98C5-4DA0-8673-01126D4E0F28

Q35754209-747C1C8F-2581-48E4-9D15-92A24F62628F

Q35754209-80A177D7-9E85-419A-A8F0-CCF16DD9B999

Q35754209-D632321B-A04A-434C-8D1D-B8E597E4BC55

Q35754209-F5F4DBF8-4C68-46EB-9F54-3E250D146482

P2860

Q35754209-01487855-9497-477E-9D3F-AC349B0C41FB

Q35754209-0871242D-12D1-49C1-A5D0-2271C4B21554

Q35754209-0A63F371-FF45-41D1-BD0F-3B96CF22453F

Q35754209-0F4ABE02-5F94-43DF-8CD5-DEB46537BE13

Q35754209-183FA23D-7DDA-4DA7-B8EC-45F0E6473CD2

Q35754209-195A179A-7BB2-4A21-BD3C-2C588E561906

Q35754209-1AB2A63D-B5F4-4260-831C-5B11F8D39DAE

Q35754209-1BE25789-1D54-46B7-87AE-E52B50F208F5

Q35754209-1F10F3E9-2CCD-46B8-BC46-CAE2AC84B7F4

Q35754209-1F4DA649-1865-4F0B-9C0D-847F3B13E784

P304

Q35754209-678F35B3-EB28-4A07-A00E-8227C614EB20

P31

Q35754209-B4C41590-8391-4981-BD4D-CFFAE7436947

P356

Q35754209-0832BABF-10E5-4CF7-8C5C-1A6F92015E30

P407

Q35754209-7D0D2325-E94E-4DDE-A426-F192B3CD8AD3

P433

Q35754209-B2856F4D-C133-4EF8-8076-67BCDF4C808C

P478

Q35754209-0E70E6BF-DF7D-4C5C-9301-6ABE2A204C20

P577

Q35754209-57F36E0F-D63D-4AC9-8DEA-C5E080523D54

P698

Q35754209-43745F4E-DA28-405D-911D-8BF402DE06FD

P921

Q35754209-EA1D59BA-40BC-4C12-B6EC-E03B13BDE7F6

P932

Q35754209-89D5F505-8072-4800-BE90-AA0F85A1E7CC

P356

RCCM.200507-1047OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Rifapentine, moxifloxacin, or ...... tuberculosis in a mouse model.

@en

P2093

Eric Nuermberger

http://www.w3.org/2001/XMLSchema#string

Ian Rosenthal

http://www.w3.org/2001/XMLSchema#string

Jacques H Grosset

http://www.w3.org/2001/XMLSchema#string

Kathy N Williams

http://www.w3.org/2001/XMLSchema#string

Sandeep Tyagi

http://www.w3.org/2001/XMLSchema#string

William R Bishai

http://www.w3.org/2001/XMLSchema#string

P2860

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

Activity of moxifloxacin against mycobacteria

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

P304

1452-1456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200507-1047OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

172

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16151038

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

1853317

http://www.w3.org/2001/XMLSchema#string